Combined hepatocellular-cholangiocarcinoma successfully treated with sorafenib: case report and review of the literature

Futsukaichi, Yuka; Tajiri, Kazuto; Kobayashi, Saito; Nagata, Kohei; Yasumura, Satoshi; Takahara, Taro; Minemura, Masami; Yasuda, Ichiro

doi:10.1007/s12328-018-0918-5

Cited by 15 publications

(10 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was probably because cHCC-CCA was similar to HCC and had a better response to treatment for recurrence. Due to the small number of the cHCC-CCA cases, the optimal treatment for cHCC-CCA recurrence remains unclear [20][21][22]. However, to our knowledge, this report is the first to describe the characteristics of cHCC-CCA recurrence in detail [12,23].…”

Section: Discussionmentioning

confidence: 88%

Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma

et al. 2020

View full text Add to dashboard Cite

Background Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a primary liver carcinoma with both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) components. We examined the clinicopathological characteristics and recurrence patterns of cHCC-CCA. Because of the rarity of cHCC-CCA, its etiology, clinicopathological features, and prognosis in comparison with other primary liver carcinoma remain unknown. Its recurrence pattern and sites in particular also need to be elucidated. Methods All patients who underwent hepatectomy for primary liver malignancies between 2005 and 2015 were retrospectively included in this study. Results Eight hundred and ninety-four hepatectomies were performed. Nineteen cases of cHCC-CCA (2.1%) in 16 patients were enrolled. Three patients underwent re-hepatectomy. The background of hepatitis viruses and tumor marker patterns of cHCC-CCA were similar to those of HCC and dissimilar to those of intrahepatic CCA (iCCA). Biliary invasion was common in cHCC-CCA and iCCA. The 5-year overall survival values of the cHCC-CCA, HCC, and iCCA patients were 44.7%, 56.6%, and 38.5%, respectively. The 5-year recurrence-free survival values of the cHCC-CCA, HCC, and iCCA patients were 12.2%, 28.7%, and 32.9%, respectively. The liver was the most common recurrence site. Unlike HCC, however, the lymph node was the second-most common recurrence site in both cHCC-CCA and iCCA. Pathological samples of the recurrent lesions were obtained in six patients, and four had cHCC-CCA recurrence pathologically. Conclusion cHCC-CCA had a mixture of characteristics of HCC and iCCA. Many cases of cHCC-CCA remained cHCC-CCA pathologically even after recurrence.

show abstract

Section: Discussionmentioning

confidence: 88%

Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…This was partially because the pattern of tumor markers and the imaging ndings of cHCC-CCA recurrence resemble those of HCC. Due to the small number of the cHCC-CCA cases, the optimal treatment for cHCC-CCA recurrence remains unclear [18][19][20]. However, to our knowledge, this report is the rst to describe the characteristics of cHCC-CCA recurrence in detail [12,21].…”

Section: Discussionmentioning

confidence: 89%

Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma

Ishii¹,

Ito

Saito

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a primary liver carcinoma with both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) components. We examined the clinicopathological characteristics and recurrence patterns of cHCC-CCA. Because of the rarity of cHCC-CCA, its etiology, clinicopathological features, and prognosis in comparison with other primary liver carcinoma remain unknown. Its recurrence pattern and sites in particular also need to be elucidated. Methods All patients who underwent hepatectomy for primary liver malignancies between 2005 and 2015 were retrospectively included in this study. Results Eight hundred and ninety-four hepatectomies were performed. Nineteen cases of cHCC-CCA (2.1%) in 16 patients were enrolled. Three patients underwent re-hepatectomy. The background of hepatitis viruses and tumor marker patterns of cHCC-CCA were similar to those of HCC and dissimilar to those of iCCA. Biliary invasion was common in cHCC-CCA and iCCA. The 5-year overall survival values of the cHCC-CCA, HCC, and iCCA patients were 44.7%, 56.6%, and 38.5%, respectively. The 5-year recurrence-free survival values of the cHCC-CCA, HCC, and iCCA patients were 44.7%, 56.6%, and 38.5%, respectively. The liver was the most common recurrence site. Unlike HCC, however, the lymph node was the second-most common recurrence site in both cHCC-CCA and iCCA. Pathological samples of the recurrent lesions were obtained in six patients, and four had cHCC-CCA recurrence pathologically. Conclusion cHCC-CCA had a mixture of characteristics of HCC and iCCA. Many cases of cHCC-CCA remained cHCC-CCA pathologically even after recurrence.

show abstract

“… 9–11 Although sorafenib, an oral multikinase inhibitor targeting vascular endothelial growth factor (VEGF), Raf, and the platelet-derived growth factor (PDGF) signaling pathway, has demonstrated a capacity to considerably improve progression-free survival (PFS) and overall survival in patients with HCC, several case-based retrospective studies have shown that its efficacy in treating cHCC-CC is limited. 12 , 13 Because of the rarity of cHCC-CC, evidence on molecular targeted therapies is still lacking but remains urgently required.…”

Section: Discussionmentioning

confidence: 99%

Remarkable Response to Olaparib in a Patient with Combined Hepatocellular-Cholangiocarcinoma Harboring a Biallelic BRCA2 Mutation

Jan

et al. 2021

OTT

View full text Add to dashboard Cite

Combined hepatocellular cholangiocarcinoma (cHCC-CC) is a rare subtype of primary liver malignancy characterized by aggressive behavior and poor prognosis. Radial surgical resection is the standard curative treatment. However, effective therapeutic options for recurrent or metastatic cHCC-CC are still lacking, mainly because of an insufficient understanding of the molecular and genomic alterations of cHCC-CC, preventing the discovery of specialized targeting therapy. Here, we present the case of a patient with metastatic cHCC-CC on first-line treatment of gemcitabine, cisplatin, and nab-paclitaxel. A comprehensive genomic profile revealed four clinically relevant single nucleotide variants ( BRCA2, PIK3C2G, RET , and TP53 ), two amplified genomic regions ( CRKL and MAPK1 ), and 11 heterozygous genomic deletions ( BAP1, CDKN2A, PTCH1, TSC1, BRCA2, RB1, RAD51, PALB2, TSC2, SMAD4 , and STK11) . The patient underwent olaparib treatment and achieved a remarkable and sustained tumor response. Our experience indicates that BRCA2 mutations could be a potential therapeutic target for patients with cHCC-CC.

show abstract

Combined hepatocellular-cholangiocarcinoma successfully treated with sorafenib: case report and review of the literature

Cited by 15 publications

References 20 publications

Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma

Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma

Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma

Remarkable Response to Olaparib in a Patient with Combined Hepatocellular-Cholangiocarcinoma Harboring a Biallelic BRCA2 Mutation

Contact Info

Product

Resources

About